SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Anthony @ Equity Investigations, Dear Anthony, -- Ignore unavailable to you. Want to Upgrade?


To: Tassi who wrote (53243)3/17/2000 8:47:00 AM
From: Anthony@Pacific  Read Replies (1) | Respond to of 122087
 
CEGE is tradin at less then cash and stcok..its amazing it got that low...



To: Tassi who wrote (53243)3/17/2000 9:21:00 AM
From: Tassi  Respond to of 122087
 
DJ Cell Genesys/Patent -2: For Large Scale AAV Vectors CEGE

17 Mar 7:54

FOSTER CITY, Calif. (Dow Jones)--Cell Genesys Inc. (CEGE) received a U.S.
patent covering methods of production of its adeno-associated viral, or AAV,
gene delivery technology.

In a press release Friday, the company said the patent claims encompass
technology for the large-scale production of AAV vectors for both clinical
trials and potential product commercialization.

Cell Genesys researches and develops gene therapies for diseases such as AIDS.

-Sam Favate; Dow Jones Newswires; 201-938-5400


(END) DOW JONES NEWS 03-17-00

07:54 AM